ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

CellCentric Announces First Patients Dosed with Inobrodib in Combination with Bispecific Antibodies in Multiple Myeloma

By: Newsfile
  • New cohorts initiated in ongoing Phase 1/2 clinical trial to evaluate inobrodib in combination with teclistamab or elranatamab for the treatment of relapsed/refractory multiple myeloma
  • Initial safety data expected by year end

Cambridge, United Kingdom and Boston, Massachusetts--(Newsfile Corp. - September 3, 2025) - CellCentric, a clinical-stage biotechnology company developing inobrodib, a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma (MM), today announced that it has initiated dosing in new cohorts evaluating inobrodib in combination with B-cell maturation antigen (BCMA) directed CD3 T-cell engagers.

The ongoing Phase 1/2 clinical trial for the treatment of patients with relapsed/refractory myeloma has now initiated new dosing cohorts evaluating inobrodib in combination with teclistamab-cqyv and inobrodib in combination with elranatamab-bcmm (NCT0406857). Approximately 40 patients are expected to receive the combination of inobrodib with either bispecific agent. Initial safety evaluation data is expected by the end of 2025. Other treatment regimens are also being assessed as part of this study.

"We're excited to build upon the positive data presented at ASH 2024, which demonstrated encouraging clinical activity for inobrodib both as a monotherapy and in combination. Based on these results, we are rapidly advancing inobrodib across several treatment settings in multiple myeloma," said CellCentric's CEO, Will West. "As a first-in-class agent with a favorable safety profile, we believe inobrodib has broad therapeutic potential, including in combination with a range of other therapies such as bispecific antibodies that have transformed the multiple myeloma treatment landscape in recent years."

In recent months, CellCentric has generated significant momentum. In April 2025, the company opened a new office in the Boston area, expanding its U.S. footprint and development capacity. In May 2025, it secured a $120 million Series C funding round, co-led by RA Capital Management and Forbion, to accelerate registration trials for inobrodib and evaluate bispecific antibody combinations. This progress has been complemented by expansion across all levels of the team, spanning clinical operations, regulatory and corporate functions.

About Inobrodib

Inobrodib is a first-in-class potential new treatment for people with cancer, and multiple myeloma in particular. It is a small molecule drug that targets p300/CBP, lowering the expression of key cancer drivers, including MYC and IRF4. It has been evaluated in over 400 patients to date and has a favorable safety and tolerability profile. Clinical activity has been seen in multiple settings, both solid tumor and hematologic malignancies. Delivered as an oral capsule, it is easy for patients to take and can be used at home without the need for intensive monitoring. Its differentiated profile may broaden use among patients who cannot tolerate or access other treatments, while its ease of administration could reduce healthcare system burden relative to more complex therapies.

CellCentric maintains development and commercial rights to inobrodib and is free to expand the program in combination with other agents.

About CellCentric

CellCentric is a privately held biotechnology company advancing inobrodib, a first-in-class, orally bioavailable p300/CBP inhibitor. Inobrodib is in a Phase II clinical trial for patients with relapsed/refractory multiple myeloma, with additional indications under consideration. CellCentric is supported by a robust IP portfolio and external validation through clinical collaborations and strategic partnerships. Headquartered in the UK with expanding U.S. operations, CellCentric is backed by a global syndicate of life science investors, including RA Captial Management, Forbion (ForCal), Morningside, Pfizer Ventures, Avego, and the American Cancer Society's BrightEdge Fund.

For more information, please contact: IR@cellcentric.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/264876

Recent Quotes

View More
Symbol Price Change (%)
AMZN  213.04
-1.43 (-0.67%)
AAPL  252.29
+4.84 (1.96%)
AMD  233.08
-1.48 (-0.63%)
BAC  51.28
+0.84 (1.67%)
GOOG  253.79
+1.91 (0.76%)
META  716.91
+4.84 (0.68%)
MSFT  513.58
+1.97 (0.39%)
NVDA  183.16
+1.35 (0.74%)
ORCL  291.31
-21.69 (-6.93%)
TSLA  439.31
+10.56 (2.46%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.